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Abstract
Background: The purpose was to describe the Nordic treatment practices and to reach a Nordic consensus for the
treatment of sebaceous eyelid carcinoma.
Methods: The treatment practices data was collected by a questionnaire with 37 questions to the Nordic
oculoplastic surgeons and analyzed. A PubMed MEDLINE database search was done to gather data on the
published treatment practices and recommendations. A working group that consisted of in minimum one senior
consultant from each leading Nordic University Eye Hospital was assigned. A structured interactive method was
used to establish the consensus.
Results: Twenty-four doctors responded to the questionnaire. 23/24 (96%) of the respondents took a biopsy before
surgery. Regional lymph node scanning was routinely done by 14/23 (61%) and a systemic screening of a
metastatic disease by 13/23 (57%). 6/22 (27%) never took conjunctival mapping biopsies and 12/23 (52%) never
screened for Muir- Torre. Respondents used Mohs surgery, frozen section or multi-stage excision with delayed
closure, and 5–6 mm was the mostly preferred margin. Sentinel lymph node biopsy was a possible option for 9/22
(41%) and cryotherapy and Mitomycin C for 6/22 (27%) respondents. 50% of respondents considered radiation as a
treatment option. 15/16 (94%) respondents always followed-up their patients, most for 5 years. Two thirds scanned
regional lymph nodes during the follow-up. Consensus was reached for 18 statements representing three domains:
preoperative work-up, treatment and follow-up.
Conclusion: Treatment practices differ in between the five Nordic countries which have similar public health care
systems. In the article the authors present a Nordic consensus for the treatment of eyelid sebaceous carcinoma.
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Background
Ocular sebaceous carcinoma is a rare malignant tumour,
associated with significant morbidity and mortality. The
tumour is rare in Latin American, Western and Nordic
countries, i.e. the estimated annual incidence is 0.41 per
million population in UK, but more common in Asian
countries [1–4]. The median age of patients is 70 to 72
years [1, 5]. The relative population-matched 10-year
survival is 79.2% [5]. Sebaceous carcinoma is often
misdiagnosed clinically in patients with a history of a
chronic unilateral conjunctivitis, blepharitis or a recur-
rent chalazion [1, 6, 7], and the delay has major adverse
effect on patient mortality [6]. The upper eyelid is most
often involved, followed by lower eyelid, palpebral con-
junctiva and caruncle [1, 8]. The tumour is originated
from Meibomian glands, or glands of Zeis and Moll. It
shows two forms of growth; nodular and more diffuse
epithelial form, the latter being more challenging to
diagnose and treat [1, 6]. Some sebaceous tumours are
associated with visceral malignancies, a rare inherited
condition called Muir-Torre [8, 9].
The Nordic countries, Denmark, Finland, Iceland,
Norway, and Sweden, have similar societies and health
care systems, and relatively small populations. All the
Nordic countries have a public health care system and
strong emphasis on evidence-based medicine and cost-
effective use of health care resources. To achieve these
goals national guidelines are common for a vast scope of
diseases. This forms an option for common Nordic
treatment guidelines for a rare disease, like eyelid seba-
ceous carcinoma. There is no data on the current treat-
ment- and follow-up practices of eyelid sebaceous
carcinoma in the Nordic countries. Furthermore, guide-
lines do not exist but the literature contains guidance
from the experience earned over the last 40 years by dif-
ferent research groups [6, 10–15].
The first aim of this study is to describe the Nordic
treatment and follow-up practices of sebaceous eyelid car-
cinoma in relation to the published data. The second aim
is to reach Nordic consensus for preoperative work-up,
treatment and follow-up of sebaceous eyelid carcinoma.
Methods
A questionnaire with 37 questions was designed with Sur-
veyMonkey®. The questionnaire was divided into four sec-
tions. The first dealt with the background information,
e.g. the country and the hospital of the respondent and
the number of patients treated for eyelid sebaceous carcin-
oma both personally and at the hospital. The second dealt
with the preoperative work-up, e.g. biopsy of the tumour,
conjunctival mapping biopsies and screening for systemic
disease and Muir-Torre. The third covered the treatment,
e.g. the surgery (frozen sections, multi stage resection with
delayed closure, Mohs surgery, aimed clinical margin, and
exenteration), sentinel lymph node biopsy (SLNB), cryo-
therapy, postoperative radiation and Mitomycin C. The
fourth focused on the clinical follow-up and the use of
screening for systemic disease. The respondents remained
anonymous.
The link to the questionnaire was sent by an email
and a following reminder e-mail to ophthalmologists on
the NOSOPRS (Nordic Society for Oculoplastic and
Reconstructive Surgery) contact mailing list. It was also
sent by a letter to the Head of all Ophthalmology De-
partments in the five Nordic Countries asking them to
forward it to their doctors involved in oculoplastics.
Additionally, the NOSOPRS contact persons in each
Nordic Country were personally contacted to deliver the
questionnaire. The responses were analyzed and pre-
sented by numerical and graphical proportions and
percentages. If the number of responses was less than 24
in a question, the actual number of responses was shown
in the denominator. Preliminary questionnaire results
were presented and discussed at the NOSOPRS meeting
in Finland in 2015.
PubMed MEDLINE database was searched for the
terms “sebaceous carcinoma” and “eyelid” until February
2019. Publications written in English and reports of at
least four patients and reviews were reviewed and state-
ments regarding work-up, treatment and follow-up were
collected. Cancer Staging refers to AJCC 8-th edition or
7-th edition. In AJCC 7-th T1 is <5mm, not invading
the tarsal plate or eyelid margin, in AJCC 8-th T1 is <10
mm. In AJCC 7-th T2a is > 5 mm but <10 mm or in-
vades the tarsal plate or eyelid margin, T2b is 10 mm
but <20 mm or involves the full thickness of the eyelid.
In AJCC8-th T2 is > 10mm but < 20mm, T2a does not
invade the tarsal plate or eyelid margin, T2b invades the
tarsal plate or eyelid margin, T2c involves the full thick-
ness of the eyelid. In AJCC 7-th T3a is > 20mm or in-
vades adjacent ocular or orbital structures or has
perineural invasion. T3b requires enucleation, exenter-
ation or bone resection. In AJCC8-th T3 is > 20 mm but
< 30mm, abc grading is equal to stage T2. In AJCC7-th
T4 is not resectable, in AJCC 8-th T4 is any eyelid
tumor that invades adjacent ocular, orbital or facial
structures [16, 17].
A working group was assigned that consisted of one se-
nior consultant, who treats eyelid sebaceous carcinoma
patients, from each leading University Eye Hospital in
Sweden, Norway, Denmark and Iceland and the original
Finnish working group of four senior consultants. A struc-
tured method was used to reach the consensus. Eighteen
structured questions were formulated and subsequently
divided between authors TL, JS, MEA, EDK and MU. In
three interactive telephone meetings all questions were
dealt with a similar protocol. In round 1 the designated
author of the question asked the structured question and
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presented the applicable results of the literature review.
Every author expressed her opinion on the question in her
turn. Areas of disagreement where discussed in the inter-
active meeting. If consensus was reached, the statement
was formulated in the meeting. In round 2 questions that
did not reach consensus in the meetings were further for-
mulated and discussed in open e-mails with all authors
until a final statement was reached. If a categorical agree-
ment was not reached the minimum level of jointly agreed
treatment practice was recommended or a conditional for-
mulation was used. Areas of disagreement were specified
in the consensus.
All authors contributed substantially to the present
study. The study has followed the Tenets of Declaration
of Helsinki.
Results
Twenty-four doctors responded to the questionnaire,
eight from each Finland and Sweden, six from Norway,
one from Denmark, and one from Iceland. As doctor in
charge of the treatment 19 respondents had treated 1–
10 sebaceous carcinoma patients in total during their
carriers, 2 respondents 11–20 patients and one doctor
over 20 patients. Two doctors did not answer the
question.
Preoperative work-up
23/24 (96%) of the respondents took a biopsy of a sus-
pected lesion before surgery. Punch biopsy was taken by
14/24 (58%) and an incisional wedge biopsy by 10/24
(42%). Conjunctival mapping biopsies were routinely
taken by 4/22 (18%) of the respondents. 12/22 (55%)
took conjunctival biopsies when the tumour was large,
clinical signs of pagetoid disease existed, conjunctiva
looked irritated or the lesion involved the eyelid margin.
9/22 (41%) took conjunctival biopsies before surgery and
5/24 (21%) at the time of surgery (Fig. 1).
Regional lymph node scanning was routinely done by
14/23 (61%) and a systemic work-up of a metastatic dis-
ease by 13/23 (57%). The reasons for occasional work-up
(6/23, 26% of respondents) were the suspicion of page-
toid disease or if an exenteration was planned. Lungs
and liver were screened by 12/23 (52%).
Screening, in any form, for Muir-Torre demonstrated
a clear dispersion between the Nordic countries. None
of the respondents routinely screened for Muir-Torre,
but in Sweden 6/8 (75%) of the respondents sometimes
screened. In the rest of the Nordic countries screening
for Muir-Torre was rare. From all respondents 12/23
(52%) never screened for Muir- Torre. The reasons for
occasionally screening were positive family cancer his-
tory, multiple malignant tumours and the patient’s re-
quest for screening.
Treatment
Figures 2 and 3 demonstrate the various treatment modal-
ities used. Mohs surgery was the preferred method in
Iceland, frozen section are used especially in Norway and
Finland and multi-stage resection in Sweden and Denmark.
Sentinel lymph node biopsy was used by 9/22 (41%).
Cryotherapy and Mitomycin C is a possible adjuvant
treatment option for 6/22 (27%) respondents. Mitomycin
C was used only in Sweden and Finland. Postoperative
radiation is considered a treatment option for 10/20
(50%) respondents, and mainly when margins are con-
sidered insufficient. The aimed clinical margin at surgery
was 3–4 mm for 8/20 (40%), 5–6mm for 9/20 (45%) and
in minimum 7mm for 3/20 (15%) respondents.
The rate of exenteration was low, only 5/19 (26%) had
done an exenteration due to extensive disease during the
last 15 years. 12/20 (60%) would though consider exenter-
ation in cases with extensive conjunctival disease or local
orbital disease. 18/20 (90%) would consider exenteration if
extensive orbital disease.
Fig. 1 Preoperative work-up used for sebaceous eyelid carcinoma in the Nordic countries
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Follow-up
15/16 (94%) respondents always follow-up their patient,
one respondent does not follow-up if the tumor is small
and a 4–5 mm margin is obtained. Eight respondents did
not answer the question.
The length of the follow-up was specified by 13 re-
spondents. 11/13 (85%) respondents followed their pa-
tient for 5 years and two for 2–3 years. The frequency of
follow-up was variable; every 2–6 months first 1–3 years
and every 6–12months last 2–5 years. No one followed-
up their patients for more than 5 years.
Scanning by CT, MRI or ultrasound for metastatic dis-
ease during follow-up is presented in Fig. 4. Most re-
spondents scan the regional lymph nodes as often and as
long as they perform the clinical follow-up. In Denmark
no annual scanning for regional lymph nodes or meta-
static disease was used.
Discussion
There was only one respondent from Denmark, and
one from Iceland. We consider the results still rele-
vant as the treatment of eyelid sebaceous carcinoma
is centralized to only two centers in Denmark and
one center in Iceland. In the other three Nordic
countries many centers treat this extremely rare dis-
ease. Due to its rarity centralization could be consid-
ered in all Nordic countries.
Preoperative work-up
Preoperatively, a comprehensive clinical evaluation in-
cluding examination of the eye, conjunctiva and caruncle
is recommended. All eyelids should be everted and pre-
auricular, submandibular, parotic and cervical lymph
nodes should be palpated [8, 13].
Fig. 2 Treatment modalities used for sebaceous eyelid carcinoma in the Nordic countries
Fig. 3 Treatment modalities used by Nordic country for verifying margins
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To establish the diagnosis a full thickness eyelid biopsy
including skin, tarsus and palpebral conjunctiva is rec-
ommended by Shields et al. [13] This can be done by an
incisional biopsy or with a round penetrating trephine.
According to Shields et al. [13] chest x-ray, liver enzyme
blood tests and work-up by MRI or CT are not neces-
sary in small lesions. However, if there is a suspicion of
orbital invasion or if the risk of nodal metastasis is high,
T2b or more (AJCC 7-th edition), a orbital CT or MRI,
thorax CT, parotid, submandibular and cervical lymph
nodes ultrasonography or CT and possible fine needle
aspiration biopsy are needed [8, 13, 18].
Conjunctival mapping biopsies are recommended to
ensure tumour margins as sebaceous carcinoma has a
tendency of intraepithelial spread. They are recom-
mended if there is suspicion of conjunctival or caruncu-
lar involvement [1, 13, 19, 20]. Shields et al. [13] report
that routinely four biopsies from the palpebral and six
from the bulbar conjunctiva should be taken. If corneal
involvement is suspected, 4 additional biopsies close to
limbus should be taken. Permanent sections are recom-
mended [13]. A recent publication by McConnell indi-
cates that the pattern and location of the primary
tumour do not correlate to a possible intraepithelial
spread and therefore standardized mapping biopsies are
always recommended [21]. Contrary to these recommen-
dations, in our study 27% of respondents never used and
54 % occasionally used conjunctival mapping biopsies.
Muir-Torre syndrome (MTS) is a rare inherited condi-
tion characterized by a combination of sebaceous carcin-
oma, other sebaceous gland tumors and other malignant
tumours; colorectal, genitourinary and breast cancer be-
ing the most common [1, 8, 9]. The opinions regarding
screening for MTS vary, but it is suggested to rule out
visceral malignancies as 6–20% of individuals with
periocular sebaceous carcinoma develop visceral tu-
mours [18, 22]. In one series with eyelid sebaceous can-
cer, MTS was found in 1 of 34 patients [1], however, in
another series, 10 of 31 patients had MTS as indicated
by clinical diagnosis of visceral malignancies [23]. His-
tory of multiple sebaceous neoplasms, other tumours
connected to Lynch syndrome (hereditary nonpolyposis
colorectal cancer) in the patient or in a relative and age
under 60 years are risk factors for MTS [24]. It is notable
that in our study 52% of respondents never screened for
MTS, which indicates a need for reconsideration.
Treatment
Full-thickness eyelid tumor resection with posterior la-
mellar is the golden standard and superior to non pos-
terior lamellar resection [25, 26]. Mohs surgery has been
recommended as treatment of sebaceous carcinoma with
excellent results with 11% recurrence rate for primary
tumours [27–31]. However, Mohs surgery is resources-
and time-demanding and not available everywhere.
Good results have also been published using frozen sec-
tions and therefore many authors prefer it [6, 8, 13, 20,
32, 33]. Some prefer multi-stage resection with perman-
ent margins and delayed closure, reporting 12% recur-
rence rates [7, 34, 35]. Multicentricity of sebaceous
carcinoma makes the securing of clear margins difficult
with all methods. There are reports with less favorable
results using both Mohs surgery [12, 36, 37] and frozen
section [12]. In our study 57% used frozen section, 50%
multi-stage resection with delayed closure and 18%
Mohs surgery, i.e. some respondents had more than one
strategy dependent on the case. The technique differed
by countries, reflecting, presumably, the facilities avail-
able and the surgeon preference.
Fig. 4 Scanning for regional lymph nodes or metastatic disease during follow-up in the Nordic countries
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A 1–3 mm margin is reported to have a recurrence
rate of 36% and a 5 mm margin a recurrence rate of
0% [10]. Good results have been reported using 4 mm
[6, 38–40], 5 mm [13, 41, 42], as well as 5 to 6 mm
margins [43]. It seems reasonable to aim for at least 4mm
margins. The majority of our respondents aimed for
5–6 mm margins.
Sentinel lymph node biopsy (SLNB) was used by 41%
of all respondents and more commonly in Finland. Re-
cent reports have recommended the use of SLNB in pa-
tients with eyelid sebaceous carcinoma with tumours
T2b (AJCC 7-th edition) or worse and in recurrent tu-
mours [15, 18, 44–48]. SLNB has been reported to be
beneficial in skin melanoma and Merkel cell carcinoma,
but SLNB has not been proven to increase survival in
eyelid malignancies [49]. Pfeiffer et al. [50] have reported
SLNB to identify nodal micrometastasis in 20% of ocular
adnexal melanoma cases. However, in tumors, such as
sebaceous carcinoma, that spread via the lymphatic sys-
tem before spreading systematically SLNB is justifiable
in tumors with a significant metastatic risk [30].
Shields et al. [13] strongly advise to use cryotherapy
for every patient, both at time of conjunctival biopsy and
final surgery [13, 14, 19]. However, in Esmaeli’s series of
50 patients, no patient was treated with cryotherapy,
with similar outcome [46].
There are few publications with few patients regarding
topical Mitomycin C treatment for sebaceous carcinoma
of the conjunctiva. Still most authors recommend it as
an alternative in treating residual in situ growth in the
conjunctiva [6, 8, 46]. In cases with extensive conjunc-
tival spread Shields et al. [51] and Xu et al. [49] recom-
mend a combination of cryo and Mitomycin C. These
options could always be considered as an alternative to
large conjunctival resections and exenteration. However,
their use was considered by only 27% of respondents,
which is surprisingly low.
Postoperative radiation after exenteration in T3 tu-
mors (AJCC 7-th edition) is reported to significantly re-
duce the risk of recurrent disease [52]. Radiation has
also been recommended for recurrent disease after exen-
teration [13] and postoperatively if insufficient margins
[46] or perineural spread [8, 30, 46] is detected. Xu et al.
[49] recommend radiation therapy for T3 or higher
(AJCC 7-th edition), pagetoid spread, nodal metastasis
or palliative care.
Radiation as primary therapy for patients who are in-
operable or refuse exenteration has shown surprisingly
good results when the dose of radiation has been 50–60
Gy. In a series published by Hata [53], all 5 patients who
got radiation as primary treatment, were alive after 5
years. Radiation might be underused in the Nordic coun-
tries as only 50% would consider postoperative radiation.
However, the risk of radiation induced dry eye, radiation
keratopathy, radiation retinopathy, cataract and even a
painful blind eye and secondary tumors should be kept
in mind.
Few of our respondents have ever performed an exen-
teration in sebaceous carcinoma patients. In older pub-
lished series the rate of exenteration was around 10% [1,
6, 7]. Today it can often be avoided with adjuvant treat-
ments, such as local mitomycin C and cryotherapy in
cases with conjunctival spread [53]. Nevertheless, 60% of
our respondents would still consider exenteration in
these cases. Exenteration should be considered if there is
extensive growth in the orbit or recurrent orbital disease
after globe sparing surgery. A very interesting recent
study [54] demonstrated that preoperative chemoterapy
reduced tumour size remarkably and spared the patients
from exenteration. The follow-up was only 18 months,
but chemoreduction seems probably a promising treat-
ment method [55].
The use of PET/CT was not included in the survey,
and none of the respondents reported using PET/CT in
the open questions. There is little published data on the
role of PET/ CT for staging and treatment of sebaceous
eyelid carcinoma, but published data support e.g. se-
lected use of PET/CT for the management of head and
neck squamous cell cancer [56]. Selected use of PET/CT
could also be considered in the management of seba-
ceous eyelid carcinoma.
Follow-up
The length of follow-up is debatable. Many studies report 5
years or longer follow-up. It is noteworthy that local recur-
rences or metastases have been reported after 60months
[7], 71months [41] and 132months [57] in patients who
have had free margins. The reported median times from
initial treatment to recurrence are 16.5 to 25months. The
reported rates for nodal recurrences are 8–23% and for dis-
tant metastasis 2–14% [6–8, 11, 26, 46, 58, 59].
A higher risk for recurrence or metastasis has been re-
ported in patients with symptoms over 6 months, in-
volvement of both upper and lower eyelids, multicentric
origin, diffuse or a non-lobular pattern, pagetoid spread,
orbital involvement, perineural invasion and stage T2b
(AJCC 7th -edition) or worse [60, 61]. In a chinese study
of 238 patients, risk factors for tumor-related death were
orbital involvement, the greatest tumor basal diam-
eter, pagetoid spread and lymph node metastasis at
initial diagnosis [62]. From United States Sa et al.
[15] report in study of 100 patients, that T3b or
worse (AJCC 8-th edition) and N1 are risk factors for
death, Lee et al. [63] report in study of 940 patients,
that older age and greater tumor size correlate with
decreased overall survival, whereas surgical treatment
or combined surgical and radiation treatment correl-
ate with increased overall survival.
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Stage T2b (AJCC 7th-edition) and stage T2c (AJCC 8-th
edition) or a more advanced disease is reported to correl-
ate with regional lymph node metastasis and T2b or T3a
or worse (AJCC 7th-edition) and stage T2c (AJCC 8-th
edition) are reported to correlate with distant metastases
[11, 15, 46, 58]. Kaliki et al. [61] estimate of lymph node
metastasis at 5 and 10 years are 0 and 0% for T1, 11and
11% for T2, 44 and 59% for T3 and 100 and 100% for T4,
Table 1 Nordic consensus for treating sebaceous carcinoma of the eyelid
Practice Statement References
Preoperative work-up
Biopsy A full thickness or in minimum incisional biopsy, request histological
analysis for sebaceous cancer.
[13]
Biopsy in chalazion surgery Request histological analysis, when the lesion is clinically suspicious or recurrent. [13]
Preoperative conjunctival
mapping biopsies
Consider, if there is suspected conjunctival involvement. [1, 13, 19–21]
Regional lymph node
scanning
Offer for category T2b (AJCC 7-th edition) or T2c (AJCC 8th- edition) and worse. [8, 13, 18]
Colonoscopy Should preferably be offered for all patients with sebaceous cancer. 1) [18, 22]
A genetic counseling for
Muir-Torre syndrome
Should preferably be offered if:
• two or more primary sebaceous tumours in one patient and/or
• under 60 years old and history of another MTS or Lynch cancer (colon, rectum,
endometrial, ovarian, small bowel, gastric, urinary tract and brain) and/or
• under 60 years old and at least one first degree relative with a tumour above. 2)
[24]
Treatment
Primary treatment method Surgery with posterior lamellar resection. [25, 26]
Clinical margin At least 4–5 mm. 3) [6, 10, 13, 38–43]
Method of surgery Multi-stage resection with delayed closure, frozen sections or Mohs surgery are
recommended to verify tumour-free margins. Conjunctival mapping biopsies
can be performed together with the final surgery if performed as multi-stage
resection with delayed closure.
[6–8, 12, 13, 20, 27–37]
Sentinel lymph node
biopsies
SLNB could be considered for tumours larger than 10 mm. [15, 18, 30, 44–50]
PET/CT PET/CT could be considered in the initial staging. [56]
Cryo In cases with pagetoid spread, additional cryotherapy to the remaining conjunctiva
is optional. The primary treatment is local resection if possible without extensive
conjunctival resection.
[13, 14, 19, 46, 53]
Mitomycin-C In cases with extensive conjunctival epithelial spread or residual conjunctival disease,
topical Mitomycin- C could be considered as an alternative to extensive surgery or
exenteration. If there is growth deep to the epithelium, Mitomycin-C is not an option.
[6, 8, 46, 49, 51]
Postoperative adjuvant
radiation
Offer radiation for tumors staged T3 (AJCC 7-th edition) or more and in cases with
perineural spread or insufficient margins. For patients who deny surgery, radiation
at a sufficient dose could be considered.
[8, 13, 30, 46, 49, 52, 53]
Preoperative
chemoreduction
In selected cases preoperative chemoreduction can be considered. [54, 55]
Follow-up
The length of the follow-up In minimum 5 years. 4) [6–8, 11, 26, 41, 46, 57–59, 61]
Clinical follow-up interval Follow-up interval is individual and depends on the post-diagnosis time-frame.
In most cases four to 6 months follow-up interval can be considered.
–
Follow-up examinations The follow-up should in minimum comprise a clinical examination and palpation
for lymph nodes. Patients should also be instructed to palpate the lymph nodes
themselves in-between follow-ups. Annual scanning (ultrasound or MRI) for regional
lymph node metastases is recommended. Scanning for distant metastases could be
considered for category T2b (AJCC 7-th edition) or T2c (AJCC 8-th edition) or worse.
[8, 15, 46, 48, 58]
Areas of disagreement
1) Some authors categorically recommended colonoscopy
2) Some authors categorically recommended Muir - Torre screening in the above defined cases
3) Some authors recommended a minimum margin of 4 mm and some 5mm
4) Some authors recommended a follow-up period of 10 years
Leivo et al. BMC Ophthalmology          (2020) 20:103 Page 7 of 9
which would justify a longer than 5 year follow-up for T3
(AJCC 7th- edition) or worse.
Few studies include recommendations for follow-up,
but some authors emphasize its importance [7, 8, 44].
Yin et al. [8] recommend a minimum of 5 years of
follow-up, including clinical examination. Patients with
an increased risk of nodal metastases are recommended
to have a clinical examination for lymph nodes and a
neck ultrasonography. Further, Yin et al. [8] recommend
imaging of the orbit for exenterated patients and pos-
sible lung scans in advanced cases. For T2b or worse
(AJCC 7-th edition) or T2c or worse (AJCC 8-th edition)
a strict regional lymph node surveillance is recom-
mended by Esmaeli et al. [46], Choi et al. [58], Lam et al.
[48] and Sa et al. [15], furthermore a surveillance for
distant metastases is recommended by Choi et al. [58]
and Sa et al. [15].
In our study most respondents used a 5-year follow-up,
which in the light of published studies seems a justified
minimum follow-up time. However, all respondents did
not follow-up their patient, which needs reconsideration.
Conclusion
Treatment practices differ in between the five Nordic
countries. Here we present a Nordic consensus for the
work-up, treatment and follow-up of eyelid sebaceous
carcinoma (Table 1).
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